10-K/A: Longevity Health Holdings Faces Delisting Threat Amidst Significant Losses and Strategic Shift to Bio-Aesthetics

Longevity Health Holdings, Inc. filed an amended annual report revealing substantial net losses, negative working capital, and ongoing Nasdaq delisting challenges, despite recent capital raises and a strategic pivot to cosmetic bio-aesthetics.

Summary

• Longevity Health Holdings, Inc. (formerly Carmell Corporation) filed an Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, primarily to amend officer certifications and include an auditor's consent.
• The company reported a net loss of $10,368,261 for the year ended December 31, 2024, compared to $15,445,087 in 2023.
• Loss from continuing operations was $10,650,464 in 2024, down from $16,205,252 in 2023.
• The company had negative net working capital of $4,921,151 and negative net cash flow from operations of $4,388,948 as of December 31, 2024.
• Management has concluded there is substantial doubt about the company's ability to continue as a going concern.
• Longevity Health Holdings is focused on longevity and healthy aging, with two cosmetic product lines: Carmell Secretome™ and Elevai Exosomes™.
• The company has paused further research and development on its innovative regenerative bone and tissue healing products (Bone Healing Accelerant BHA and Tissue Healing Accelerant THA) to focus on cosmetic commercialization.
• Gross sales for the year ended December 31, 2024, were $90,829 from its first five cosmetic skincare products.
• In January 2025, the company completed a private placement, raising gross proceeds of $1,851,849.
• Also in January 2025, the company acquired Elevai Exosomes™ cosmetic skincare and haircare business, which had net sales of approximately $2,500,000 in 2024.
• The company received Nasdaq delisting notices for failing to meet the minimum bid price ($1 per share) and Market Value of Listed Securities ($35 million) requirements, and has appealed the delisting determination.
• Research and development expenses decreased by 58% to $1,054,310 in 2024, due to strategic realignment and cessation of clinical studies for long-term product candidates.
• General and administrative expenses increased by 42% to $3,715,340 in 2024, primarily due to higher insurance costs and personnel salaries/benefits, partially offset by cost reductions.
• The company is involved in a lawsuit regarding convertible notes, with Puritan Partners LLC seeking $2,725,000 in damages and other remedies.
• Kendra Bracken-Ferguson ceased serving as CEO in January 2025, and Rajiv Shukla was re-appointed as CEO.

Sentiment

Score: 2

Explanation: The company is in a precarious financial position, evidenced by significant net losses, negative working capital, negative cash flow from operations, and an explicit 'going concern' warning from management and auditors. The Nasdaq delisting threat is severe. While strategic shifts and recent capital raises offer some positive direction, they are insufficient to offset the immediate financial distress and operational challenges. The ongoing litigation further adds to uncertainty. The overall sentiment is highly negative, reflecting high risk and uncertainty regarding the company's viability.

Positives

• Net loss from continuing operations decreased by 34% from $16,205,252 in 2023 to $10,650,464 in 2024, indicating some improvement in operational efficiency or reduced expenses.
• Net cash used in operating activities decreased significantly by $3,959,260 (47.4%) from $8,348,208 in 2023 to $4,388,948 in 2024, driven by cost reductions from restructuring activities.
• The company successfully closed a 2025 Private Placement, raising gross proceeds of $1,851,849, providing much-needed capital.
• The acquisition of Elevai Exosomes™ business adds a product line that generated approximately $2,500,000 in net sales in 2024, expected to grow in 2025, diversifying revenue streams.
• Strategic realignment to focus on cosmetic skincare and haircare products with near-term commercial potential could lead to faster revenue generation.
• The company launched its first five cosmetic skincare products in 2024, generating $90,829 in gross sales, with an additional seven products expected to launch in the first half of 2025.
• The company has implemented significant operating expense reductions, including terminating executives and a redundant facility lease, resulting in annual savings of approximately $3,000,000 to $4,000,000 starting in 2024.

Negatives

• The company reported a substantial net loss of $10,368,261 for the year ended December 31, 2024, and has incurred net losses each year since its inception.
• As of December 31, 2024, the company had negative net working capital of $4,921,151, indicating a severe liquidity crunch.
• Negative net cash flow from operations of $4,388,948 in 2024 highlights the company's inability to generate sufficient cash from its core business activities.
• Management has explicitly stated there is substantial doubt about the company's ability to continue as a going concern.
• The company received Nasdaq delisting notices for failing to meet the minimum bid price ($1 per share) and Market Value of Listed Securities ($35 million) requirements, posing a significant threat to its public listing.
• A lawsuit filed by Puritan Partners LLC alleges breach of convertible notes obligations and seeks damages totaling $2,725,000, plus additional fees and interest, which could further strain financial resources.
• The company's stock price was $0.1542 as of March 27, 2025, significantly below the Nasdaq minimum bid price requirement.
• The company's reliance on third-party suppliers for raw materials and manufacturing poses supply chain risks if these vendors fail to perform or maintain quality control.
• The success of cosmetic products is highly subjective and dependent on consumer satisfaction with aesthetic results, which may vary and impact repeat business.
• The company has limited experience as a commercial company, facing significant risks in marketing and sales of its cosmetic products.
• The cosmetics industry is highly competitive, with large multinational companies having greater financial, technical, and marketing resources.
• The company's intellectual property may not be sufficient to protect its products from competition, and enforcing trade secret claims is difficult and expensive.

Risks

• Limited experience as a commercial company, potentially leading to unsuccessful marketing and sales of cosmetic products and inability to generate meaningful product revenue.
• Commercial success depends on attaining and maintaining significant market acceptance of current products among consumers, physicians, and other buyers/sellers.
• Products derived from human tissue carry the potential for disease transmission, despite strict quality controls.
• Inability to successfully address quality issues with products could harm brand reputation and adversely impact business, financial condition, and results of operations.
• Product liability lawsuits could result in substantial liabilities and limit commercialization of products.
• Success is largely dependent on consumer satisfaction with the aesthetic results of products, which are highly subjective.
• Strategic transactions (e.g., acquisitions) could impact liquidity, increase expenses, and distract management.
• Failure to protect or enforce intellectual property or confidential proprietary information could hinder effective competition and limit partnership/acquisition appeal.
• Uncertainty in obtaining and maintaining patent protection for products and technology.
• Risk of infringing intellectual property rights of others, leading to lawsuits, damages, or forced cessation of product sales.
• Need for substantial additional capital to support growth plans, which may not be available on acceptable terms, if at all, hampering growth and adversely affecting business.
• Substantial doubt about the company's ability to continue as a going concern.
• Involvement in litigation (e.g., convertible notes dispute) that may materially adversely affect the company.
• Substantial competition from larger, more resourced companies in the cosmetics industry.
• Adverse effects from changing economic conditions, including interest rates and inflation, and geopolitical conflicts.
• Difficulties in managing future organizational growth due to increased responsibilities and need for additional resources.
• Potential delisting from Nasdaq due to non-compliance with minimum bid price and market value of listed securities requirements, reducing visibility, liquidity, and stock price.
• Volatility in the price of Common Stock due to various factors, including commercialization results, R&D failures, litigation, and market conditions.
• Future resales of Common Stock could cause the market price to drop significantly.
• Reduced disclosure requirements as an emerging growth company may make Common Stock less attractive to investors.
• No anticipated cash dividends, making capital appreciation the sole source of gain for stockholders.
• Provisions in corporate documents and Delaware law may inhibit takeovers, potentially limiting stock price and entrenching management.
• Significant disruptions of information technology systems, computer system failures, or breaches of information security could adversely affect business operations and lead to loss of data or intellectual property.
• Misconduct by employees or others acting on behalf of the company could lead to significant liability and reputational harm.
• Reliance on third parties for raw materials, packaging, manufacturing, and packaging, posing risks if these vendors fail to perform or maintain quality control.
• Challenges in educating physicians on the proper use and benefits of products as alternatives to existing treatments.
• Ineffective inventory management could adversely affect results of operations.

Future Outlook

The company anticipates growing revenue from the continued commercialization of its cosmetic products, particularly from the newly acquired Elevai business which generated $2.5 million in 2024 sales. They expect to launch an additional seven skincare products in the first half of 2025. Management also plans to explore out-licensing certain research and development programs to enhance liquidity. However, the company acknowledges that its current cash may not be sufficient for the next 12 months and will need to raise additional capital through equity or debt issuances, with no assurance of favorable terms or timely completion. The company believes it has a path to regaining Nasdaq compliance but cannot guarantee success.

Management Comments

• "We are focused on longevity and healthy aging, encompassing the latest scientific advances in regenerative bio-aesthetics. Our products are aimed to help people look and feel their best at any age."
• "We believe that we currently have adequate sources of supply for all our products."
• "We believe that we maintain a good working relationship with our employees and have not experienced any difficulty in recruiting staff for our operations."
• "Management has determined there is substantial doubt about our ability to continue as a going concern."
• "We believe that we have a path to regaining compliance with Nasdaq's listing requirements, but no guarantee can be provided that we will be successful in doing so."
• "Management of the Company believes that its obligations under the Convertible Notes and Convertible Note Warrants have been satisfied and that no additional payments are due to the Holders."

Industry Context

The company operates in the rapidly growing skincare and haircare markets, which were approximately $280 billion in 2022 and are expected to grow at a 6.4% compound annual growth rate (CAGR). The aesthetics market is growing 36% faster than pharmaceuticals. Longevity Health Holdings focuses on the 'physician-dispensed' channel, where consumers increasingly seek advice from medical professionals due to market saturation and confusion. This strategy aligns with a trend towards medically-backed cosmetic solutions. However, the beauty industry is highly concentrated with large multinational companies, posing significant competition for smaller entrants like Longevity Health Holdings. The company's pivot from regenerative bone and tissue healing to bio-aesthetics reflects a strategic choice to pursue a market with more immediate commercial potential, aligning with current consumer trends in cosmetic enhancement.

Comparison to Industry Standards

• The document states the skincare and haircare markets were approximately $280 billion in 2022 and are expected to grow at a 6.4% CAGR, and the aesthetics market is growing 36% faster than pharmaceuticals. However, the document does not provide specific comparable companies, projects, or their results to benchmark Longevity Health Holdings' financial performance (e.g., revenue, profitability, market share) against industry standards or competitors like LOreal, Estée Lauder, Coty, Revlon, Shiseido, Johnson & Johnson, and Procter & Gamble, which are mentioned as large multinational competitors. Therefore, a direct quantitative comparison of results is not possible based on the provided text.

Management Changes

Corporate Governance

Legal Proceedings

• On November 8, 2023, Puritan Partners LLC filed a complaint against the Company (Puritan Partners LLC v. Carmell Regen Med Corporation et al., No. 655566/2023, New York Supreme Court, New York County).
• Puritan asserts claims for breach of obligations under Convertible Notes and Convertible Note Warrants, and non-compliance with providing freely tradeable shares.
• Puritan seeks remedies including damages totaling $2,725,000 through November 1, 2023, additional fees and interest, costs, attorneys' fees, and an order of foreclosure on its security interest.
• The Company carried an accrual for interest payable of $1,175,845 as of December 31, 2024 and 2023 related to the Convertible Notes.
• In July 2024, the Court dismissed four of the eight claims in the complaint without prejudice.
• The case is currently in the discovery phase, expected to last through June 2025.
• Management believes its obligations under the Convertible Notes and Convertible Note Warrants have been satisfied and no additional payments are due, and intends to defend vigorously.

Related Party Transactions

• In the 2024 Private Placement, the Company's Chief Executive Officer, Rajiv Shukla, invested $25,000, purchasing 8,680 shares of Common Stock at $2.88 per share.
• The Company engaged a Placement Agent for the 2024 and 2025 Private Placements, of which Board member Patrick Sturgeon is a managing partner. The Company paid the Placement Agent $212,212 in fees and $39,726 in legal fees for the 2024 Private Placement, and incurred $60,000 in legal fees (of which $35,000 was unpaid as of Dec 31, 2024) and paid $127,925 in fees for the 2025 Private Placement.
• In conjunction with the 2024 Private Placement, the Company issued a warrant for 89,787 shares of Common Stock to the Placement Agent.
• In conjunction with the 2025 Private Placement, the Company issued a warrant to purchase up to 556,195 shares of Common Stock to the Placement Agent.
• During 2023, entities affiliated with a partnership where a Board member (Rich Upton) is a general partner purchased $50,000 of the 2023 Promissory Notes, which were repaid in 2024 with 19,000 shares of Common Stock valued at $50,000.
• As of the AxoBio Merger Closing Date, AxoBio had $5,610,000 in promissory notes outstanding to Burns Ventures, LLC (Burns Notes), whose owner was a former AxoBio stockholder. These notes were transferred to the Buyers in the AxoBio Disposition.
• AxoBio used OrthoEx for 3PL services; the former Chief Executive Officer of AxoBio (who advised the Company) has an equity interest in OrthoEx. The Company incurred $26,700 (2024) and $41,752 (2023) in expenses for OrthoEx services.
• The Company used Ortho Spine Companies, LLC for consulting and marketing services, owned by a former advisor. The Company incurred $0 (2024) and $79,167 (2023) in expenses for Ortho Spine services.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from future equity raises, potential loss of investment due to ongoing net losses, negative working capital, and the 'going concern' doubt. The Nasdaq delisting threat could severely impact liquidity and the market price of their Common Stock. The reverse stock split, if implemented, carries uncertainty regarding its effect on share price.
• **Employees:** The company has fifteen full-time employees as of March 27, 2025. Strategic realignment and cost reductions (e.g., executive terminations, lease termination) have already impacted personnel. Future financial instability could lead to further workforce reductions or impact compensation.
• **Customers:** The strategic pivot to cosmetic products aims to meet professional care providers' and discerning retail consumers' demands. Product quality issues or negative publicity could harm brand reputation and consumer satisfaction, impacting sales.
• **Suppliers:** The company relies on third-party suppliers for raw materials, packaging, manufacturing, and logistics. Financial instability could affect the company's ability to pay suppliers, potentially disrupting the supply chain.
• **Creditors:** Holders of convertible notes are in litigation with the company over alleged additional payments, indicating potential default risks and legal costs. The 'going concern' doubt raises concerns about the company's ability to satisfy its liabilities in the normal course of business.

Next Steps

• Launch an additional seven skincare products in the first half of 2025.
• Continue efforts to regain compliance with Nasdaq's listing requirements, including the appeal hearing scheduled for April 15, 2025.
• Explore out-licensing certain research and development programs to enhance liquidity.
• Potentially raise additional capital through equity or debt issuances.
• Continue to defend against the lawsuit filed by Puritan Partners LLC, with the case currently in the discovery phase expected to last through June 2025.
• Comply with new MoCRA requirements for cosmetics, including mandatory GMPs (expected October 2025), facility registration, and product listing.

Key Dates

Recommendation

Keywords

Longevity Health Holdings, SEC Filing, 10-K/A, Financial Report, Cosmetics, Skincare, Haircare, Bio-aesthetics, Carmell Secretome, Elevai Exosomes, Going Concern, Nasdaq Delisting, Net Loss, Working Capital, Cash Flow, Private Placement, Acquisition, Elevai Labs, Risk Factors, Intellectual Property, Regulatory Compliance, FDA, FTC, MoCRA, Litigation, Convertible Notes, Management Change, Rajiv Shukla, Kendra Bracken-Ferguson, Regenerative Medicine, Bone Healing, Tissue Healing